Pfizer has received permission from the CFDA to market an oral treatment for rheumatoid arthritis in China. Xeljanz® (tofacitinib citrate), a Janus kinase inhibitor, is indicated for adult patients with moderately to severely active rheumatoid arthritis whose disease does not respond to methotrexate (MTX). Pfizer says Xeljanz, which was granted marketing approval in the US in 2012, is the first oral JAK inhibitor approved for RA patients in China.
Source: ChinaBio Today
Please to leave a comment.
Over the years, investors have seen how exciting opportunities in innovation have matured into solid investments. Advances in AI, Big Data, Clean Technology and Health Care have all led ... Event Info